GEN-1 Immunotherapy Continues to Show Promise in Newly Diagnosed Advanced Ovarian Cancer Patients

GEN-1 Immunotherapy Continues to Show Promise in Newly Diagnosed Advanced Ovarian Cancer Patients
Combining the DNA-based immunotherapy GEN-1 with standard of care neoadjuvant chemotherapy continues to show promise in patients with newly-diagnosed advanced ovarian cancer who will undergo interval debulking surgery, according to the most recent data of the OVATION study. In the first 12 patients dosed, which include patients from the fourth and final cohort, the combination therapy has shown promising efficacy signs, including 100% disease control rate and 75% objective response rate, with no dose limiting toxicities. “These early results have impressed our investigators which accounts for the rapid patient accrual in the study.  The consistency and robust nature of the data across all four cohorts and the encouraging clinical responses underscore the potential of GEN-1 to serve as an effective, safe IL-12 immunotherapy in ovarian cancer,” Nicholas Borys, MD, chief medical officer, Celsion Corporation, said in a press release. “In particular, we see improvements across a number of important and meaningful measures used to assess ovarian cancer, which reinforce our confidence in this IL-12 immunotherapy approach and provide a strong rationale for continued development of GEN-1 for the treatment of ovarian cancer," Borys added. "We look forward to the translational data which, along with the clinical findings, will assist in the design of our registrational program.” Celsion's GEN-1 is a lipid vesicle that targets specifically tumor cells and that contains a DNA molecule with the I
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *